Better communication between surgeons and pathologists will help to inform understanding of vaginal mesh complications.
A review of pathology evaluations of explanted vaginal mesh specimens highlights a need for greater communication between surgeons and pathologists, says a team of researchers including John O.L. DeLancey, MD, a member of the Contemporary OB/GYN editorial board. Better communication will help to ensure accurate documentation, diagnosis, and opportunity for study of the pathophysiology of mesh complications, they claim.
“We recommend improved communication between surgeon and pathologist first and foremost through more complete documentation to aid the pathologist's examination and enable understanding of the pathophysiology of mesh complications,” the authors write in the July-August issue of Female Pelvic Medicine & Reconstructive Surgery. “This is particularly germane as this subject is ‘under the microscope,’ as it were, by health care providers, regulatory bodies, the legal system and patients.”
The researchers, of the Division of Female Pelvic Medicine and Reconstructive Surgery, Department of Obstetrics and Gynecology, University of Michigan Health System, Ann Arbor, studied the process by which specimens from vaginal mesh removal operations are submitted to pathology departments for evaluation.
Their most striking finding was of limited surgical team documentation of mesh product type or material type on pathology requisition forms. While such requisition details might seem trivial, the authors note, these details help guide the pathologic exam. Explants containing metal or other nonbiological material generally cannot be submitted for standard tissue processing and sectioning. This is because metal and other foreign materials may not be sectioned and made into slides by standard means.
“No history was provided to the pathologist in 24.5% and the mesh type or product name was indicated on only 7% of requisitions. In the absence of this information, 1 in 5 specimens were described as “metal” or “metallic,” reports that would clearly be confusing and potentially damaging in the current climate of escalating regulatory and medicolegal concerns,” said Tovia Smith, MD.
Grossly undetectable metal fibers may prevent sectioning. Even fine polypropylene mesh fibers may make tissue evaluation difficult due to splintering or lack of adhesion to slides.
The group suggests that either gross or histopathologic examination is appropriate for mesh explants. They found that documentation of clinical history, mesh product, and material was frequently incomplete and associated with increased submission of tissue for histology and inaccurate gross impression of material type.
They recommend improved documentation to aid pathologic examination and enable future study of the pathophysiology of mesh complications.
Smith TM, Smith SC, DeLancey JO, et al. Pathologic evaluation of explanted vaginal mesh: Interdisciplinary experience from a referral center. Female Pelvic Med Reconstr Surg. 2013;19(4):238-241.
Phase 2b safety data for Sildenafil Cream against FSAD reported
August 26th 2024In a recent study published in The Journal of Sexual Medicine, Sildenafil Cream, 3.6% was indicated as safe and well-tolerated for use against female sexual arousal disorder in healthy premenopausal women.
Read More
Study: Pelvic floor dilator reduces pelvic floor muscle injury during vaginal delivery
August 6th 2024A new pilot study published in the International Urogynecology Journal found that Materna Medical’s Prep Device, a pelvic floor dilator, reduced full levator ani muscle avulsion during vaginal delivery in first-time mothers.
Read More
Similar success rates for synthetic and nonsynthetic slings in SUI treatment
July 31st 2024A study found that both synthetic and nonsynthetic slings show similar success rates for treating stress urinary incontinence in women, with synthetic slings demonstrating improved operative outcomes and reduced complications.
Read More
First hysterectomy using miniaturized MIRA Surgical System performed
July 30th 2024Virtual Incision Corporation has announced the successful performance of the first benign hysterectomy using their miniaturized robotic-assisted surgery device, MIRA, in a clinical trial assessing its safety and efficacy.
Read More